Peptomyc 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
OMO-103 / Peptomyc
Osteomyc, NCT06650514: A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma

Recruiting
2
10
Europe
OMO-103
Vall d'Hebron Institute of Oncology, Peptomyc S.L., Osteosarcoma Institute, Curing Kids' Cancer Foundation, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Oregon Health and Science University, The Morgan Adams Foundation, The Kristen Ann Carr Fund
Osteosarcoma, Osteosarcoma in Children
06/26
12/26
2020-003802-30: A two-part study to investigate the safety, pharmacokinetics and effects of a new medication called OMO-103 as a treatment for Advanced Tumours.

Not yet recruiting
1/2
90
Europe
Omomyc, OMO-103, Concentrate for solution for infusion
Peptomyc S.L., Peptomyc S.L.
Solid tumours, Cancer, Diseases [C] - Cancer [C04]
 
 
MYCure, NCT04808362 / 2020-003802-30: Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours

Terminated
1/2
22
Europe
OMO-103
Peptomyc S.L., Peptomyc S.L.
Advanced Solid Tumors, Pancreatic Cancer, CRC
12/22
01/23
OMO-103-02, NCT06059001: Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered Iv in Patients with PDAC

Recruiting
1
30
Europe
OMO-103, Nab-Paclitaxel, Gemcitabine
Peptomyc S.L.
Metastatic Pancreatic Cancer
12/25
03/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
OMO-103 / Peptomyc
Osteomyc, NCT06650514: A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma

Recruiting
2
10
Europe
OMO-103
Vall d'Hebron Institute of Oncology, Peptomyc S.L., Osteosarcoma Institute, Curing Kids' Cancer Foundation, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Oregon Health and Science University, The Morgan Adams Foundation, The Kristen Ann Carr Fund
Osteosarcoma, Osteosarcoma in Children
06/26
12/26
2020-003802-30: A two-part study to investigate the safety, pharmacokinetics and effects of a new medication called OMO-103 as a treatment for Advanced Tumours.

Not yet recruiting
1/2
90
Europe
Omomyc, OMO-103, Concentrate for solution for infusion
Peptomyc S.L., Peptomyc S.L.
Solid tumours, Cancer, Diseases [C] - Cancer [C04]
 
 
MYCure, NCT04808362 / 2020-003802-30: Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours

Terminated
1/2
22
Europe
OMO-103
Peptomyc S.L., Peptomyc S.L.
Advanced Solid Tumors, Pancreatic Cancer, CRC
12/22
01/23
OMO-103-02, NCT06059001: Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered Iv in Patients with PDAC

Recruiting
1
30
Europe
OMO-103, Nab-Paclitaxel, Gemcitabine
Peptomyc S.L.
Metastatic Pancreatic Cancer
12/25
03/26

Download Options